Definium Therapeutics

Biotechnology companywww.definiumtherapeutics.com

17

MENTIONS

11

EPISODES

8

PODCASTS

Sep 21, 2026

The Psychedelic News Feed

The Psychedelic News Feed

Psychedelics in D.C., FDA’s Framework, and New Zealand’s MDMA Prescribers

Sep 21 · 1 Mention

Josh HartmanHOST

13:59

It runs at around 3,000 words, so if you're looking for more detail, that's the place to go.

Josh HartmanHOST

14:04

The first story is that LSD drug developer Definium Therapeutics shared last week data from its second phase 3 study of LSD, it calls DT120, in generalised anxiety disorder.

Josh HartmanHOST

14:15

It was positive just like the first one, and it becomes the third successful phase 3 readout from the company since June.

Josh HartmanHOST

14:22

It expects to submit a new drug application for its LSD candidate in the first half of 2027.

The People's Pharmacy

The People's Pharmacy

Show 1487: Hair Loss and Nail Problems: A Dermatologist’s Guide to What Actually Works

Sep 18 · 1 Mention

Joe GraedonHOST

4:21

After decades of controversy, LSD may actually receive FDA approval to treat generalized anxiety disorder, or GAD.

Joe GraedonHOST

4:32

That's because the drug company Definium Therapeutics just reported promising results from a third clinical trial.

Joe GraedonHOST

4:40

The company has tested this hallucinogen for both depression and anxiety.

Joe GraedonHOST

4:45

It's reported that one dose of 100 micrograms of LSD produced a statistically significant and clinically meaningful improvement in the Hamilton Anxiety Rating Scale.

Here & Now Anytime

Here & Now Anytime

UN investigators say US likely committed war crimes in Iran

Sep 17 · 1 Mention

Elaine ChenGUEST

13:26

Yeah, it seems like we're getting pretty close.

Elaine ChenGUEST

13:29

So this week, a company called Definium Therapeutics announced results from a large trial showing that its LSD drug helped relieve anxiety for patients.

Elaine ChenGUEST

13:42

Um, and this was actually its second positive study.

Elaine ChenGUEST

13:44

It had already reported a positive study earlier this year.

Unknown podcast

Episode 9: Engineering Around the Problem - 18-MC, Tabernanthalog & Next-Generation Analogs

Sep 17 · 4 Mentions

speaker_0HOST

21:00

And then what happened?

speaker_1HOST

21:01

Then in 2019, as mainstream interest in psychedelic medicines and their derivatives began to explode, the program was acquired by a larger psychedelic biotech firm called MindMed.

speaker_0HOST

21:12

And MindMed gave it a developmental codename, MM110, or the generic drug name Zolunacant.

speaker_0HOST

21:19

And they actually did what had to be done.

speaker_0HOST

21:21

They took it into humans.

speaker_1HOST

21:22

Yes, they did.

speaker_1HOST

21:23

In 2022, MindMed successfully completed a phase one clinical trial in healthy human volunteers.

speaker_0HOST

21:29

Let's remind you, the listener, what phase one is actually for.

Unknown podcast

Episode 4 · From Field to Feedstock - Cultivation, Sourcing & Sustainability

Sep 17 · 3 Mentions

speaker_1HOST

35:39

It really did.

speaker_1HOST

35:40

Under the developmental code name MM110, the molecule was acquired by a biotechnology company called MindMed in 2019.

speaker_0HOST

35:48

They pushed it through preclinical development and by 2022 successfully completed a phase one clinical trial in healthy human volunteers.

speaker_1HOST

35:56

And the phase one data validated the core hypothesis.

speaker_1HOST

36:15

But, and this is a massive, the reality of drug development is that brilliant science is always ultimately subordinate to corporate strategy and capital

speaker_0HOST

36:23

markets.

speaker_0HOST

36:24

In 2023, just months after the successful phase one safety readout, MindMed abruptly announced they were discontinuing all active development of MM110.

speaker_0HOST

36:32

They shelved the entire 18MC program.

Unknown podcast

Episode 7: Polypharmacology - How Ibogaine Actually Works (and Noribogaine)

Sep 17 · 2 Mentions

speaker_1HOST

14:20

Yeah, it was such a compelling, pristine proof of concept.

speaker_0HOST

14:23

So compelling that a biotechnology company called MindMed eventually acquired the rights to it.

speaker_0HOST

14:28

They named it MM110 or Zulunacant.

speaker_0HOST

14:31

They took it all the way through phase one clinical trials and healthy human volunteers in 2022.

speaker_1HOST

14:39

It is exactly the kind of story the pharmaceutical industry loves.

speaker_1HOST

14:42

However, as scientists, we have to follow the data where it actually leads, not where we want it to go.

speaker_1HOST

14:47

Despite that successful phase one safety profile, MindMed formally announced in 2023 that they were shelving the active development of MM110.

speaker_0HOST

14:56

Due to what they termed strategic reprioritization, right?

Unknown podcast

Episode 1 · Origins — From Bwiti Ritual to Addiction Medicine

Sep 17 · 1 Mention

speaker_0HOST

32:55

Who took it over?

speaker_1HOST

32:56

A company named Savant HWP advanced the molecule, and in 2019, it was acquired by the psychedelic biotech firm MindMed.

speaker_1HOST

33:04

They designated it as Developmental Compound MM110.

speaker_0HOST

33:09

They took it all the way to a phase one clinical trial in healthy human volunteers, which concluded in 2022.

First Opinion Podcast

First Opinion Podcast

Definium's new psychedelics data, and a reprieve for international scientists

Sep 17 · 1 Mention

Alison DeAngelisHOST

2:21

Can you start off telling us a little bit more about the big clinical trial readout that we got this week?

Elaine ChenHOST

2:26

So this week, Definium Therapeutics said that its LSD therapy helped relieve patients' anxiety in a second phase three trial.

Elaine ChenHOST

2:37

So that sets the company up to be able to file for approval with the FDA.

Elaine ChenHOST

2:42

Notably, most other psychedelic biotechs are developing drugs for depression or PTSD.

The Readout Loud

The Readout Loud

Definium's new psychedelics data, and a reprieve for international scientists

Sep 17 · 1 Mention

Allison DeAngelisHOST

2:21

Can you start off telling us a little bit more about the big clinical trial readout that we got this week?

Elaine ChenHOST

2:26

So this week, Definium Therapeutics said that its LSD therapy helped relieve patients' anxiety in a second phase three trial.

Elaine ChenHOST

2:37

So that sets the company up to be able to file for approval with the FDA.

Elaine ChenHOST

2:42

Notably, most other psychedelic biotechs are developing drugs for depression or PTSD.

FDA hears input on psychedelics, PDUFA, lung cancer’s next-gen therapies boost survival

Sep 16 · 1 Mention

Jeff AxtHOST

7:44

Well, before we move on to the next part of the FDA's busy week, let's stay on psychedelics for a minute because one of those front runners I mentioned is Compass.

Jeff AxtHOST

7:51

I also mentioned Definium Therapeutics.

Jeff AxtHOST

7:52

They had some more results for us this week.

Heather McKenzieHOST

7:55

Yes, they did.

1 more episode mentions Definium Therapeutics.

Create an account to see the whole feed, search across every transcript, and follow the entities you care about.

Sign up to see more Already have an account? Log in